The Conversation (0)
BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), a company focused on developing new smartphone-based AI-powered mental healthcare solutions, is excited to announce its upcoming listing on the Australian Securities Exchange (ASX) on 4 April 2024 at 12:00pm AEDT 9:00am AWST under the ticker code BB1. BlinkLab, a company started by neuroscientists at Princeton University, over the past several years has fully developed a smartphone-based test for early diagnosis of autism, ADHD, and other neurodevelopmental conditions. Funds raised will be used to finalize an FDA Class II medical device registration study in autism in partnership with leading US university hospitals.
- BlinkLab Limited shares to commence trading on the Australian Securities Exchange (ASX) on 4 April 2024 at 12:00pm (AEDT) under the ticker code BB1.
- The oversubscribed IPO raised A$7m at $0.20 per share.
- Capital raised will be used to progress smartphone-based autism diagnostic test into FDA registrational study, initiate further clinical studies in other programs including ADHD as well as continue to advance in-house AI/ML algorithms.
BlinkLab Chairman, Brian Leedman, said: “I believe BlinkLab is the next groundbreaking venture in digital healthcare. Our innovative approach leverages the power of smartphones, AI and machine learning to deliver autism screening tests specifically designed for children as young as 18 months old. This will aid healthcare providers to identify these children at a much younger age than presently available providing a pathway to effective treatment and better outcomes for the child and their families. This cutting-edge digital technology is poised to capture the imagination of major industry players, eager to embrace transformative solutions in healthcare.”
The BlinkLab Test combines a smartphone’s ability to deliver stimuli and acquire data using computer vision with a secure cloud-based platform for data storage and analysis. In the experiments, each audio and/or visual stimulus is presented with millisecond-precise control over parameters such as timing, amplitude, and frequency. To maintain participant attention, an entertaining video of choice is shown with normalized audio levels. Participants’ responses are measured by the smartphone’s camera and microphone and are processed in real time using state-of-the art computer vision techniques, fully anonymized, and transferred securely to the analysis portal. There, BlinkLab’s in-house AI/machine learning algorithms then perform clustering and statistical analysis to identify the predictive value of the test in a particular data set. This AI-based smartphone based platform is designed to be used under supervision of medical healthcare practitioners.
Company’s previous clinical trials have shown an impressive success rate in the diagnosis of autism, achieving sensitivity of 85 percent and specificity of 84 percent. These trials are very similar to regulatory studies required by US FDA and have shown a much higher accuracy of BlinkLab Test compared to currently approved products that do not use computer vision and a smartphone.
BlinkLab team has experienced management and leading experts in the field of machine learning, autism, and brain development, bridging the most advanced technological innovations with groundbreaking scientific research. These include Princeton University Professor Sam Wang, a co-founder of BlinkLab, who is recognized as a global key opinion leader in the field of brain research and autism. Professor Wang serves as Chair of Blinkab's Independent Advisory Board.
Click here for the full ASX Release
This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
BB1:AU
BlinkLab Limited Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
BlinkLab Limited
Investor Insight
BlinkLab’s transformative AI-based healthcare technology is at the forefront of innovations in the global medical field that are quickly gaining traction among keen investors.
Overview
BlinkLab (ASX:BB1) offers a smartphone-based diagnostic platform that leverages computer vision, artificial intelligence (AI) and machine learning (ML). A company started by neuroscientists at Princeton University, Blinklab has developed its novel technology over several years, providing an app-enabled, smartphone-based diagnostic tool for evaluating children with neurodevelopmental conditions such as autism and ADHD.
The app turns a smartphone into a diagnostic tool that helps to conduct remote and rapid tests that can assist in diagnosing neurodevelopmental conditions. BlinkLab’s smartphone app provides a screening tool that can help with diagnoses much earlier than the age that children are typically assessed at present (approximately 5-6 years old). It is also a remote (i.e., accessible) and inexpensive means of beginning the assessment process, which can typically be very costly and take up to multiple years currently.
BlinkLab’s smartphone app facilitates early diagnosis, reduces costs, and improves accuracy.
BlinkLab’s smartphone-based technology, which uses AI and machine learning (ML), makes it attractive to investors. Like other industries, AI is becoming very popular in the healthcare sector. According to Statista, the AI healthcare market is expected to proliferate from $11 billion in 2021 to $187 billion in 2030. The increasing use of AI is driven by advanced ML algorithms, access to data, and use of 5G technology. AI and ML technologies can evaluate and analyze enormous volumes of data faster than humans.
Artificial intelligence, and particularly machine learning, has the potential to serve as the great equaliser for many behavioural healthcare concerns like autism. According to recent data, 97 percent of adults in the United States own a cellular device, and nine in ten own a smartphone. A 2022 Global State of Digital report by We Are Social shows 66.9 percent, or about 5.34 billion, of the world’s population are mobile users. As these percentages continue to rise and internet-powered devices become ubiquitous, access to digital health services can become democratised on a global scale. While autism spectrum disorder (ASD) services are currently restricted to relatively privileged populations, digital solutions powered by emerging data, science, and methodologies can make access to autism therapy more accessible.
Large players are investing in this segment to tap into the vast potential of these new technologies. One such example was Pfizer’s acquisition of ResApp. In October 2022, Pfizer acquired Queensland University startup ResApp Health for $179 million. ResApp developed a smartphone technology to detect respiratory diseases using cough analysis accurately.
Furthermore, big tech companies such as Apple, Amazon, Microsoft and Alphabet are also now venturing into the AI healthcare market.
Company Highlights
- Australia-based BlinkLab (ASX:BB1) is focused on transforming mental healthcare through an AI-enabled smartphone application, a breakthrough technology developed with Princeton University.
- The company’s innovative approach leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old. This marks a significant advancement, considering traditional diagnoses typically occur around five years of age, often missing the crucial early window for effective intervention.
- Once approved by regulators, this cutting-edge digital technology is poised to capture the imagination of both investors and major pharmaceutical companies, eager to embrace transformative solutions in healthcare.
- BlinkLab is led by an experienced management team and leading experts in the field of machine learning, autism and brain development, bridging the most advanced technological innovations with groundbreaking scientific research. The company is chaired by Brian Leedman, an experienced biotechnology entrepreneur and founder of ResApp Health, a digital diagnostic company recently acquired by Pfizer.
Key Technology and Applications
Neurobehavioral assays of brain function can reveal fundamental mechanisms underlying neuropsychiatric conditions, but typically require centrally located equipment in a laboratory test facility. Consequently, these tests are often unpleasant for participants, as they often require instruments attached to their face and cannot be used at scale in daily clinical practice, particularly with paediatric patients.
BlinkLab has developed a smartphone-based software platform, known as ‘BlinkLab Test’, to perform neurobehavioural testing that is free from facial instruments or other fixed location equipment.
This AI-based platform is designed to be used at home or in similarly comfortable environments, either independently or with the assistance of a caregiver, while following instructions from the smartphone application. The tests include, but are not limited to, eyeblink conditioning (EBC), which is a form of sensory-motor associative learning, prepulse inhibition of the acoustic startle response (PPI), which measures the ability to filter out irrelevant information through sensorimotor gating, startle habituation, which measures the ability for the intrinsic damping of repetitive stimuli and sensory adaptation, and habituation of the eye blink response, which serve as biomarkers for neurological and psychiatric disorders.
The BlinkLab Test App combines a smartphone’s ability to deliver stimuli and acquire data using computer vision with a secure cloud-based portal for data storage and analysis. In the tests, each audio and/or visual stimulus is presented with millisecond-precise control over parameters such as timing, amplitude and frequency. To maintain participant attention, an entertaining movie of choice is shown with normalised audio levels. Participants’ responses are measured by the smartphone’s camera and microphone, and are processed in real time using state-of-the art computer vision techniques. Response data is then fully anonymised, and transferred securely to the analysis portal. There, BlinkLab’s in-house AI/ML algorithms then perform clustering and statistical analysis to identify the prediction value of the experiment in the particular data set.
BlinkLab Test was initially developed as a prescription diagnostic aid to healthcare professionals (HCP) considering the diagnosis of ASD in patients 18 months through 72 months of age that are at risk for developmental delay. In collaboration with Princeton University in the United States and Erasmus Medical Center in the Netherlands, the company has conducted several trials using BlinkLab Test as an early assessment tool for autism. Autism represents a global challenge, with 1 in 36 children in the U.S. having autism, up from the previous rate of 1 in 44. With no early tests currently available to detect the condition, many children are diagnosed with the condition as late as the age of five.
Blinklab’s mobile app can aid in early detection, facilitating diagnoses as early as two years of age and resulting in earlier personalised interventions and monitoring. The testing process is also far more comfortable than traditional means of diagnoses, as the child can watch their favourite movie or cartoon on the phone, and the app will record their reactions, providing key information on the functioning of the brain.
BlinkLab will be subject to regulatory oversight as a medical device and must clear clinical studies. Previous clinical trials completed by Blinklab have shown impressive indicators of success, achieving sensitivity levels of 85 percent and specificity levels of 84 percent. The company notes that these trials are very similar to those that are required by the United States Food and Drug Administration (FDA) for approval and have shown much higher levels of accuracy compared to currently approved products.
In order for the BlinkLab Test technology to be used as a clinical aid in the diagnosis of ASD, BlinkLab will need to complete a pivotal registrational study, and subsequently apply for FDA registration and reimbursement for the tests. The registrational study intends to recruit up to 500 subjects. Enrolment for this study is expected to begin in 2024, with study completion expected by mid-2025. The potential to participate in a disruptive and scalable AI-powered technology close to regulatory approval should attract attention from big medical technology companies.
Research and clinical studies
BlinkLab engages and partners with research and medical institutions across the globe to further test and develop its technology.
In May 2024, BlinkLab initiated a clinical study in partnership with US-based Turning Pointe Autism Foundation to enroll up to one hundred children previously diagnosed with autism and one hundred children without an autism diagnosis. The data obtained during this collaboration will be used to finalise the data collection and processing algorithms and AI/ML models ahead of the FDA registrational study.
The company is also participating in a clinical study of patients with spinocerebellar ataxias, conducted by Columbia University, New York, to study the effect of aerobic physical exercise on neuroplasticity in adults with spinocerebellar ataxias (SCA).
To further improve and accelerate the diagnostic evaluation of ADHD, BlinkLab forged a major research and clinical partnership with Mental Care Group (MCG) in The Netherlands, the fifth largest outpatient mental health care provider in Europe.
To validate BlinkLab’s platform for the assessment of functional neurological disorder (FND), the company has partnered with Bates College in Maine for a clinical study that aims to characterise the behavioural time course of Pavlovian eyeblink conditioning and acoustic startle habituation. It will validate the BlinkLab smartphone test for use as a remote neurobehavioral testing and diagnostic tool for FND.
At Erasmus University Medical Center, BlinkLab’s smartphone-based remote assessment, including eyeblink conditioning and prepulse inhibition of the acoustic startle reflex, is being used, among other tools, in a clinical study to set-up an overarching at-home testing lab, named the Digital Dementia Lab, to identify, develop and test a variety of digital biomarkers
measuring clinically relevant behaviour for improving early accurate diagnosis of dementia.
BlinkLab is also working with Monash University in Australia to evaluate BlinkLab as a medical device for monitoring the therapeutic effects of ketamine on cognitive processes whereby sensory information is converted into decision making. Results from this study can help facilitate cognitive behavioural therapy outcomes in patients with psychiatric conditions such as depression, schizophrenia, epilepsy, and post-traumatic stress disorder.
BlinkLab also recently signed a partnership for more clinical trialling with INTER-PSY, a large centre in the Netherlands that specialises in autism, offering assistance with diagnostics and treatments. This study also mirrors the study design of the Company’s developing FDA regulatory trial, which will be needed for future approval of BlinkLab Test as an approved diagnostic tool in the United States.
Management Team
BlinkLab is led by an experienced management team and directors with a proven track record in building companies and vast knowledge in digital healthcare, computer vision, AI and machine learning. The company’s chairman, Brian Leedman, is an experienced biotechnology entrepreneur and founder of ResApp Health, a digital diagnostic company for respiratory conditions, which was recently acquired by Pfizer for $179 million before reaching FDA approval for their main diagnostic product.
Dr. Henk-Jan Boele – Founder and Chief Executive Officer
Henk-Jan Boele is an assistant professor of neuroscience at the Medical Center of Erasmus University and a researcher at Princeton University. He obtained his PhD from Erasmus University in 2014. Boele has always been pushing scientific and methodological boundaries, and received numerous government and industry grants in the field of neuroscience.
Peter Boele – Founder and Chief Technology Officer
Peter Boele holds a bachelor’s degree in history and philosophy from Leiden University. He has over 20 years of experience in software development and has worked with Erasmus University, Leaseweb, Kaboom Informatics and Insocial.
Dr. Anton Uvarov – Founder and Chief Operational Officer
Anton Uvarov holds a Ph.D. from the University of Manitoba and an MBA from the Haskayne School of Business. He has rich experience in bio-technology investments with a particular focus on neuroscience and has successfully led several IPOs. He started his career as a biotechnology analyst with Citigroup, US.
Dr. Bas Koekkoek – Founder and Chief Scientific Officer
Bas Koekkoek is an assistant professor at Erasmus Medical Center. Koekkoek has been working at the Department of Neuroscience mainly in the role of rapid prototype of new technology and techniques for neuroscience. He has numerous publications in the area of brain development including Nature and Science journals.
Professor Sam Wang – Founder and Chair of Advisory Board
Sam Wang holds a PhD from Stanford University. He is a professor of neuroscience at Princeton University, has published over 100 articles on the brain in leading scientific journals and has received numerous awards. He gives public lectures on a regular basis and has been featured in The New York Times, The Wall Street Journal, NPR, and the Fox News Channel.
Professor Chris de Zeeuw – Founder and Scientific Advisor
Chris de Zeeuw is chairman of the Department of Neuroscience at Erasmus MC in Rotterdam and vice-director at the Netherlands Institute for Neuroscience in Amsterdam. De Zeeuw has received over 100 grants, including the Pioneer Award from ZonMw and the ERC advanced grant. In 2006, he received the Beatrix Award for Brain Research from Her Majesty the Queen; in 2014, he became an elected member of the Dutch Academy of Arts & Science; and in 2018, he received the international Casella Prize for Physiology.
Revolutionising Mental Health Care Through Mobile Solutions
Tech 5: Meta Plans Multibillion AI Bet, Apple Reveals iOS 26 at WWDC 2025
1. Meta's AI strategy takes shape with US$14.8 billion deal
Meta has a massive deal in the works with Scale AI, as per information provided by sources to multiple outlets.
On June 7, Bloomberg broke the news that Meta was in discussions for a potential investment of over US$10 billion in the AI firm. Then, on Tuesday (June 10), The Information reported Meta would acquire a 49 percent stake in Scale AI for US$14.8 billion, valuing the startup at US$28 billion, a two-fold increase from its valuation in 2024.
The news was followed by Tuesday reports from the New York Times and Bloomberg saying that Meta would be unveiling a new AI research lab focused on achieving superintelligence.
It will include Alexandr Wang, who is Scale AI's founder and CEO, among other Scale AI employees.
CEO Zuckerberg reportedly acquired additional talent for the lab by offering lucrative compensation packages to engineers from multiple other tech firms, including Google (NASDAQ:GOOGL) and OpenAI.
2. Apple's WWDC disappoints investors
Shares of Apple fell by over 2 percent on Monday (June 9) and closed 1.43 percent lower after new developments and features revealed at its annual Worldwide Developers Conference (WWDC) failed to impress investors.
Apple’s forthcoming software updates featured subtle improvements, such as a revamped operating system (OS) and AI capabilities that were noticeably toned down compared to the previous year's unveiling.
Among the new additions to Apple devices are in-app live translation, call screening, AI-driven information analysis and more sophisticated image generation capabilities thanks to its partner OpenAI.
The company also said it would provide developers with offline functionality for its on-device AI models.
The biggest development was the introduction of Liquid Glass, a new design language and graphical user interface developed to unify the visual experience across Apple’s operating systems.
Also part of the push for unification, Apple shared it is switching to an iOS naming system using a number based on calendar year after its release, meaning the next release will be iOS 26.
Apple briefly mentioned the long-awaited AI-powered upgrade to its Siri assistant that was announced at WWDC 2024. During the previous conference, executives hinted that the new Siri would be released with iOS 18, which came out last September without the upgrade.
While no release date was provided at the event, Senior Vice President of Software Engineering Craig Federighi said that the company looks forward to sharing more details “in the coming year.” The company reaffirmed that timeline in a Bloomberg report after anonymous sources told the publication Apple is aiming for a spring 2026 release.
Shares of Apple closed down 3.88 percent for the week.
3. Amazon to build nuclear-powered data centers in Pennsylvania
Amazon announced plans on Monday to invest at least US$20 billion in expanding its data center infrastructure in Pennsylvania, including the construction of two new data center campuses. One campus will be in Luzerne County, south of Scranton, alongside Talen Energy's (NASDAQ:TLN) Susquehanna nuclear power plant. The second campus will be built north of Philadelphia in Bucks County, at the site of what was once a steel mill.
“Pennsylvania is competing again — and I'm proud to announce that with Amazon's commitment of at least $20 billion to build new state-of-the-art data center campuses across our Commonwealth, we have secured the largest private sector investment in the history of Pennsylvania,” Pennsylvania Governor Josh Shapiro (D) said in a press release.
Later, on Wednesday (June 11), Talen announced the expansion of its nuclear energy partnership with Amazon. The collaboration was originally formed in 2022, and will now supply AWS data centers with up to 1,920 megawatts of electricity from its plant, double its previous commitment of 960 megawatts.
The two companies also shared plans to explore the development of small modular reactors in the state.
4. Oracle reaches new heights on earnings report
Oracle (NYSE:ORCL) reported its fiscal Q4 and full-year 2025 earnings on Wednesday, revealing total Q4 revenue of US$15.9 billion, above analyst estimates and a year-over-year increase of 11 percent.
Earnings per share were US$1.70, which also exceeded expectations of US$1.64.
The software maker’s cloud infrastructure business grew by 50 percent year-over-year in fiscal year 2025, and Oracle projected a further increase of 70 percent in cloud infrastructure sales over the next year.
Oracle performance, June 9 to 13, 2025.
Chart via the Investing News Network.
CEO Safra Catz's news during the earnings call that the Stargate joint venture is “not yet formed” had little bearing on the company’s share price. The positive report sent shares to a new high of US$202.44, and they continued climbing to close Friday up 23 percent since the start of the week.
5. NVIDIA CEO highlights AI job creation, European AI deals at VivaTech
In a week of announcements that coincided with the VivaTech 2025 conference in Paris, NVIDIA CEO Jensen Huang showcased his company’s role as a full-stack AI infrastructure provider.
His message during his keynote presentation on Wednesday was a stark contrast to Anthropic CEO Dario Amodei’s warning earlier this week that AI could lead to widespread job displacement.
On the contrary, Huang said that AI will create new industries and demand for jobs. He also noted that quantum computing technology is at an inflection point, with the potential to solve problems that currently demand years of processing by classical computers. His comments came just one day after IBM (NYSE:IBM) unveiled its newest roadmap, which includes plans for a new quantum data center and the IBM Quantum Starling, which the company says will be the world's first large-scale, fault-tolerant quantum computer.
Cementing NVIDIA's role as a global infrastructure leader, Huang shared plans to develop European sovereign AI models through a newly announced partnership with US-based, AI-powered search engine Perplexity and French sovereign AI start-up H Company. Developers will be able to access and fine-tune Perplexity’s models through Hugging Face, a platform for model sharing and collaboration.
DGX Cloud Lepton, NVIDIA's sovereign-ready AI cloud platform, will host the models on European infrastructure to comply with local data privacy and localization requirements. Huang said that, with over 20 active AI factory initiatives in the region, he anticipates a tenfold increase in Europe's AI computing capacity within two years.
Also on Wednesday, insiders for Bloomberg reported that NVIDIA and Samsung Electronics (KRX:005930) will make minority investments in robotics software developer Skild AI as part of the company’s Series B funding round.
The round is led by a US$100 million investment from SoftBank (TSE:9434) and will result in a US$4.5 billion valuation, according to the report. Sources with insider knowledge said that NVIDIA will invest US$10 million and Samsung will put in US$25 million in a strategic move aimed at boosting the companies' influence in the consumer robotics sector.
Don't forget to follow us @INN_Technology for real-time news updates!
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
Tech 5: CoreWeave and Applied Digital Strike Deal, Startup Anduril Raises US$2.5 Billion
Read on to dive deeper into this week's top tech stories.
1. Applied Digital and CoreWeave strike major deal
Applied Digital was the top performer on the S&P 500 (INDEXSP:.INX) on Monday (June 2) after the company announced two long-term lease agreements with cloud infrastructure company CoreWeave.
Under the terms of the agreements, Applied Digital will deliver 250 megawatts of IT load to host CoreWeave's AI and high-performance computing infrastructure at its Ellendale, North Dakota, data center campus. The arrangements are expected to generate approximately US$7 billion in total revenue for Applied Digital.
News of the deal sent shares of Applied Digital up by over 22 percent to close at US$10.14 on Monday afternoon. CoreWeave’s share price saw an increase of 3.35 percent, closing at US$118.24.
The companies finished the week up 67 percent and 20 percent, respectively.
2. Broadcom shares slip post-earnings
Broadcom shares rose 3.2 percent on Tuesday (June 5), hitting a record high of US$264.89 after the company announced that it began shipping its latest networking chip, the Tomahawk 6.
However, enthusiasm faded after Broadcom reported its earnings after the markets closed.
Despite beating estimates on both earnings and revenue, the chip supplier’s forecast for the third quarter wasn’t enough to impress investors, who sent its share price down in after-hours trading.
The company is calling for Q3 revenue of US$15.8 billion, below analysts' forecasts of US$15.71 billion.
“High expectations drove a bit of downside,” Bernstein analyst Stacy Rasgon said in a note.
Despite this, Broadcom ended the week priced at US$246.93, 1.5 percent above Monday’s opening price.
3. Cohere targets new funding round
Canadian AI company Cohere is seeking US$500 million in new funding, targeting a valuation of US$5.5 billion to US$6.5 billion, according to a Financial Times report released on Sunday (June 3).
The outlet cites three sources with inside knowledge of ongoing discussions that are still in early stages.
The company was founded by former Google (NASDAQ:GOOGL) researchers; it prioritizes enterprise users and specializes in privacy solutions. Cohere has not released any consumer apps, but has debuted a family of open-source models: Aya, as well as North, a platform available to limited users that allows businesses to develop customized AI agents. According to the sources, Cohere doubled its annual recurring revenue to more than US$100 million in May.
Apple, Broadcom, Applied Digital and CoreWeave performance, June 2 to 6, 2025.
Chart via Google Finance.
4. Delays and court rulings challenge Apple's strategies
The Financial Times reported on Monday that Apple’s rollout of AI services in China is being delayed by Beijing regulators due to the ongoing trade war between China and US President Donald Trump’s administration.
In February, Apple made a deal with Alibaba (NYSE:BABA) to power Apple Intelligence using Alibaba’s proprietary Qwen large-language models. However, the rollout has been stalled, potentially due to ongoing geopolitical tensions, although Chinese regulators have not confirmed any particular reasons for the delay.
In other news, a federal appeals court denied Apple’s request for a stay of a court order that forbids the company from collecting commission on external payment links, a result of its legal battle with Epic Games.
Apple “bears the burden of showing that the circumstances justify an exercise of (our) discretion,” according to the order. “After reviewing the relevant factors, we are not persuaded that a stay is appropriate.”
The rejection by the appellate court forces Apple to adhere to the original ruling, which aims to increase competition and offer users diverse payment choices. The decision's consequences are substantial, potentially impacting Apple’s existing revenue structure. Additionally, it could reshape the overall landscape of the mobile app market.
5. Anduril valuation soars after latest funding round
Defense startup Anduril Industries, known for supplying weapons to the US government, has secured US$2.5 billion in a new funding round led by Founders Fund, Peter Thiel's venture capital firm. The firm contributed US$1 billion, according to Anduril Executive Chairman Trae Stephens, who spoke to Bloomberg Television on Thursday (June 5).
The newest round has more than doubled the company’s valuation, bringing it to US$30.5 billion.
Anduril has become a key player in modern defense tech with its autonomous drones, surveillance towers and AI-driven systems, part of a broader shift toward software-defined warfare.
Don't forget to follow us @INN_Technology for real-time news updates!
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
BlinkLab Limited Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects